Kim, Min Chul
Ahn, Youngkeun
Kim, Moo Hyun
Kim, Seok-Yeon
Hong, Taek Jong
Rhee, Moo-Yong
Kim, Sang-Hyun
Hong, Soon-Jun
Kim, Hyungseop
Kim, Weon
Chae, In Ho
Kang, Duk-hyun
Kim, Byeong-Keuk
Kim, Hyo-Soo
Clinical trials referenced in this document:
Documents that mention this clinical trial
A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia
https://doi.org/10.1007/s40256-023-00590-9
Article History
Accepted: 22 May 2023
First Online: 3 July 2023
Declarations
:
: This work was supported by Hanmi Pharmaceutical Company. The authors thank all investigators in all medical institutions for this study. The study interpretation, writing of the manuscript, and the decision to publish manuscript were the sole responsibility of the authors and were thus independent of the funders. Hanmi Pharmaceutical Company supported the supply of investigational products, laboratory tests, and clinical research coordinator expenses.
: Min Chul Kim, Youngkeun Ahn, Moo Hyun Kim, Seok-Yeon Kim, Taek Jong Hong, Moo-Yong Rhee, Sang-Hyun Kim, Soon-Jun Hong, Hyungseop Kim, Weon Kim, In Ho Chae, Duk-hyun Kang, Byeong-Keuk Kim, and Hyo Soo Kim declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.
: This study was approved by the Institutional Review Board of each institute.
: Written informed consent was obtained from all participants before starting the study.
: The data used and/or analyzed during the current study are available from Hanmi Pharmaceutical Company, but restrictions apply to the availability of these data, which were used under the license of the current study. Data are available from the authors upon reasonable request and with the permission of Hanmi Pharmaceutical Company.
: Not applicable.
: Not applicable.
: Conceptualization: MCK and H-SK. Data curation; MCK, YA and H-SK. Analysis: MCK, YA and H-SK. Funding acquisition: H-SK. Investigation: MCK and H-SK. Methodology: MCK and H-SK. Project administration: YA and H-SK. Resources: MCK and H-SK. Supervision: YA, MHK, S-YK, TJH, M-YR, S-HK, HK, WK, IHC, DK, B-KK and H-SK. Validation: MCK and YA. Visualization: MCK and H-SK. Writing: MCK and H-SK. Reviewing: MCK, YA, MHK, S-YK, TJH, M-YR, S-HK, S-JH, HK, WK, IHC, DK, B-KK and H-SK. All authors read and approved the final manuscript.